Estimaciones de analistas de Wall Street para Adaptive Biotechnologies Corporation (ADPT): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 11 |
| Mantener | 4 |
| Venta | 2 |
| Venta fuerte | 0 |
| Analistas totales | 17 |
| Calificación media (1-5) | 0.53 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.10 | ||
| 2026-07-29 | $-0.25 | $-0.13 | -87.1% |
| 2026-05-05 | $-0.13 | $-0.16 | +18.8% |
| 2026-02-05 | $-0.09 | $-0.19 | +52.6% |
| 2025-11-06 | $0.06 | $-0.18 | +133.3% |
| 2025-08-05 | $-0.17 | $-0.24 | +29.2% |
| 2025-05-05 | $-0.20 | $-0.34 | +41.2% |
| 2025-02-12 | $-0.23 | $-0.27 | +14.8% |
Ratios de valoración
| Precio / Valor contable | 30.44 |
| EV / EBITDA | -282.58 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $38.4M | $55.7M | $85.1M | $98.4M | $154.3M | $185.3M | $170.3M | $179.0M | $277.0M |
| Coste de Ventas | $15.7M | $19.7M | $22.3M | $22.5M | $49.3M | $57.9M | $75.6M | $72.1M | $71.4M |
| Beneficio Bruto | $22.8M | $36.0M | $62.8M | $75.9M | $105.0M | $127.4M | $94.7M | $106.9M | $205.6M |
| I+D | $32.0M | $39.2M | $70.7M | $116.1M | $142.3M | $141.8M | $122.1M | $103.0M | $93.8M |
| Generales y Administrativos | $32.7M | $44.9M | $68.8M | $110.9M | $170.0M | $184.1M | $172.5M | $157.6M | $167.3M |
| Gastos Operativos | $66.4M | $85.8M | $141.2M | $228.7M | $314.0M | $327.6M | $321.8M | $269.4M | $262.7M |
| Beneficio Operativo | -$44.5M | -$49.8M | -$78.4M | -$152.8M | -$209.0M | -$200.2M | -$227.0M | -$162.5M | -$57.1M |
| EBITDA | -$37.8M | -$43.8M | -$70.6M | -$144.3M | -$193.3M | -$175.2M | -$189.3M | -$128.8M | -$29.8M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | $4.2M | $13.8M | $11.6M | $11.8M |
| Beneficio Antes de Impuestos | -$42.8M | -$46.4M | -$68.6M | -$146.2M | -$207.3M | -$200.4M | -$225.3M | -$159.6M | -$59.5M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$42.8M | -$46.4M | -$68.6M | -$146.2M | -$207.3M | -$200.2M | -$225.2M | -$159.5M | -$59.5M |
| BPA | $-0.41 | $-0.44 | $-0.47 | $-1.06 | $-1.46 | $-1.00 | $-1.56 | $-1.08 | $-0.39 |
| BPA Diluido | $-0.41 | $-0.44 | $-0.47 | $-1.06 | $-1.46 | $-1.00 | $-1.56 | $-1.08 | $-0.39 |
| Acciones en Circulación (Diluidas) | $105.4M | $105.4M | $124.3M | $131.2M | $140.4M | $142.5M | $144.4M | $147.1M | $151.7M |
Precio
| Precio | $24.20 |
| Capitalización | $3.9B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: BEAM · CDTX · CPRX · IDYA · IRON · LEGN · MLYS
Explorar sector: Healthcare · Biotechnology
Más secciones de ADPT: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones